The Research Of Cetuximab Conjugated Tubulin Inhibitorin Of Effectiveness And Targeting In The Treatment Of Human Lung Cancer

Objective:The study intends to explore the effectiveness and targeting of Cetuximab conjugated tubulin inhibitorin in the A549 cell xenografts in nude mice.Method:1 、 Subcutaneous injection of A549 lung cancer cells in the 20 4-6-week-old BALB/c female nude mice to preparation of the animal model of hunan lung tumor xenografts. And then randomly divided mice into 4 groups with 5 each, grouped as follows: Cetuximab conjugated tubulin inhibitorin group(ADC group), Cetuximab group, cisplatin group, concrol group(normal saline group). Measured once every 3days for each group of tumor volume after intravenous injection. According to volume of 21 days to make the tumor growth trend.2、TUNEL method to observe pathological morphology changes and apoptosis for tumor cells, and then calculate the rate of apoptosis for each group.3、ELISA method to determine the concentrations of tubulin inhibitorin(MMAE)in tumor tissues and blood by intravenous injection of ADC drug after 7 days and compare to each other, to further validate the targeting of ADC drug.Result:1、Cetuximab conjugated tubulin inhibitorin can significantly inhibit the growth of lung cancer xenografts compared with the control group and cetuximab group, and compared with cisplatin group also have better inhibition.2、The apoptosis rate of Cetuximab conjugated tubulin inhibitorin group and cisplatin group is higher than other two groups.3、Cetuximab conjugated tubulin inhibitorin group can be targeted into the lung cancer tissue after intravenous injection.Conclusion:Cetuximab conjugated tubulin inhibitorin be targeted into A549 human lung cancer xenografts and has obvious inhibiting cytotoxicity to lung cancer.